Artiva Biotherapeutics reports Q2 EPS ($22.00) vs. ($14.09) last year

As of June 30, Artiva had cash, cash equivalents, and short-term investments of $46.6M. In addition, Artiva completed its IPO in July 2024 in which it sold 14,920,000 shares of its common stock, including partial exercise of the overallotment option, for gross proceeds of $179M. “Artiva is at an inflection point as we advance AlloNK in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, Artiva’s CEO. “With two trials in autoimmunity underway, we are focused on the potential of AlloNK in delivering effective, safe, and accessible cell therapies for patients with devastating autoimmune disease.”